Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models. Tucker ER, Jimenez I, Chen L, Bellini A, et al. Clin Cancer Res 2023;29:1317-1331.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tucker ER, Jimenez I, Chen L, Bellini A, et al. Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models. Clin Cancer Res 2023;29:1317-1331.
PMID: 36602782